The investment propositions for VAL and DDDD are completely different.
VAL have released initial results from a single arm, open label, dose escalation phase I/IIa study in 12 patients. The objective of any phase I/IIa trial is to look at safety and dosing and early signs of efficacy to establish whether the drug merits further development. VAL's RNS suggests that the safety looks good, there are early signs of efficacy but they haven't yet established the optimum dosing levels. They now will need to run further trials to do this.
4D Pharma's Blautix study is a randomised, blinded phase IIb trial in around 370 patients. I believe that DDDD have confirmed that they intend to license Blautix rather than develop it in-house.
So the 2 drugs are at completely different stages of development and you simply can't make comparisons between a 12 patient phase 1 study and a 370+ patient randomised study in terms of investment proposition. This isn't intended to be at all critical of VAL or its results and of course we still don't know the Blautix results but IMO you can't make any judgement calls about 4D based on what we've seen at VAL. IMO, DYOR etc. etc.
Great piece on Amryt courtesy of richpassi on advn
'Midas verdict: Amryt Pharma is unlike many biotech firms because it is already making money and growing fast. Brokers forecast sales of at least $200million for 2021, with significantly higher revenues in subsequent years. Investors who bought three years ago have done well and may choose to bank some profit at £1.95. But they should retain most of their shares as the stock has considerable potential. New investors may fancy a punt on this one, too. '
Ergomed seem to be going from strength to strength and market clearly very happy with interims:-
· Total revenue growth of 14.8% · Service fee revenue growth of 25.9% (18.0% on a like-for-like basis) · Adjusted EBITDA £9.1 million up 40.0% · Order book up 22.0% since 1 January 2020 providing high visibility into H2 2020 and beyond · Strong net cash balance of £14.1 million
Link to interview with Richard Barfield below and good to hear what he has to say about dividends.
Meant to add and perhaps worth noting that Lindy durrant's presentation is under the 'Next Gen ADC’s & Bispecific Antibodies' section rather than 'Monoclonal Antibodies & Cellular Therapy' - make of that what you will
Lindy Durrant will be presenting at 4th Annual Next-Gen Immuno-Oncology Congress next month. Title of her presentation:-
'Avidimabs, Fc engineering to enhance the avidity of mabs, panel of mabs recognised tumour associated glycans and has pioneered a new antibody engineering technology which enhances the avidity of mabs, termed Avidimabs'
Think we should clarify that these patents only cover cancer but as you have highlighted, Scancell have only scratched the surface of the potential of Moditope. The sooner those trials get underway the better.